

Claims

1. A pharmaceutical composition having antitumor activity prepared by extracting 0-100wt% of powdered Pulsatillae Radix and 0-100wt% of powdered Ulmaceae cortex in a solvent at the temperature of below 60°C, filtering and lyophilizing the extract, and then admixing the lyophilized powder with conventional auxiliaries, or admixing the above extracted solution with auxiliaries, then filtering and lyophilizing the mixture, and then formulating the lyophilized powder to a pharmaceutical preparation by a conventional method used in the pharmaceuticals.

2. A pharmaceutical composition having antitumor activity prepared by extracting 0-100wt% of powdered Pulsatillae Radix and 0-100wt% of powdered Ulmaceae Cortex, provided that the content of Pulsatillae Radix and Ulmaceae Cortex is over 30wt%, and one or more ingredients selected from 0-70% of powdered Ginseng Radix and 0-70wt% of Glycyrrhizae Radix in a solvent at the temperature of below 60°C, filtering and lyophilizing the extract, and admixing the lyophilized powder with conventional auxiliaries, or admixing the extracted solution with auxiliaries, filtering and lyophilizing the mixture, and then formulating the lyophilized powder to a pharmaceutical preparation by a conventional method used in the pharmaceuticals.

3. The pharmaceutical composition according to claims 1 or 2, wherein the solvent is selected from water, alcohol, acetone, ethyl acetate and mixtures thereof and the composition is formulated in a form selected from powder, granule, tablet, capsule, injectable powder and ointment.

4. The pharmaceutical composition according to claims 1 or 2, wherein the auxiliaries are one or more selected from diluent, binding agent, disintegrator, preservative, indolent, isotonic agent and lubricant.

5 5. A process for the preparation of a pharmaceutical composition having antitumor activity comprising extracting 0-100wt% of powdered Pulsatillae Radix and 0-100wt% of powdered Ulmaceae cortex in a solvent at the temperature of below 60°C, filtering and lyophilizing the extract, and admixing the lyophilized powder with conventional
10 auxiliaries, or admixing the above extracted solution with conventional auxiliaries, then filtering and lyophilizing the mixture, and then formulating the lyophilized powder to a pharmaceutical preparation by a conventional method used in the pharmaceuticals.

15 6. A process for the preparation of a pharmaceutical composition having antitumor activity comprising extracting 0-100wt% of powdered Pulsatillae Radix and 0-100wt% of powdered Ulmaceae cortex, provided that the content of Pulsatillae Radix and Ulmaceae Cortex is over 30wt%, and one ore more ingredients selected from 0-70wt% of
20 powdered Ginseng Radix and 0-70wt% of powdered Glycyrrhizae Radix in a solvent at the temperature of below 60°C, filtering and lyophilizing the extract, and admixing the lyophilized powder with conventional auxiliaries, or admixing the above extracted solution with auxiliaries, then filtering and lyophilizing the mixture, and then formulating the
25 lyophilized powder to a pharmaceutical preparation by a conventional method used in the pharmaceuticals.

7. The process according to claims 5 or 6, wherein the solvent is

selected from water, alcohol, acetone, ethyl acetate and mixtures thereof and the composition is formulated in a form selected from powder, granule, tablet, capsule, injectable powder and ointment.

- 5 8. The process according to claims 5 or 6, wherein the auxiliaries are one or more selected from diluent, binding agent, disintegrator, preservative, indolent, isotonic agent and lubricant.

10

15

20

25